Upload
trinhhanh
View
219
Download
3
Embed Size (px)
Citation preview
Validation of New Molecular Assays
Kimberlee Musser, PhD
Wadsworth Center-NYSDOH
August 12, 2008
Clinical Laboratory Evaluation Program
All clinical laboratories in New York State required to be permitted through the Clinical Laboratory Evaluation Program (CLEP).
Any Laboratory (including Wadsworth Center) wishing to perform a molecular assay must submit an application for approval to use on patient specimens
http://www.wadsworth.org/labcert/TestApproval/index.htm
ValidationExamples
CLEP Submission Guidelines
Nucleic Acid Amplification Tests
* SYBR Green, melt point analysis alone is not sufficient
CLEP Approval Process for Use of Nucleic Acid Amplification Assays
SOPMDetailed protocolMolecular workflow detailsQuality Assurance
Evidence of proficiency test program including # of samples; passing rateValidation dataReferencesSpecimen Result Report (positive, negative, and inconclusive samples with all disclaimers)References including package inserts
Where to Start?
CLIA regulations (42 CFR Section 493.1253) indicate that for laboratory-developed assays, commonly referred to as “home-brew assays,” the following performance characteristics be determined: analytical sensitivity, analytical specificity (including the effect of interfering substances), precision, accuracy, measuring range of test results, and reference intervals (normal values).
http://www.wadsworth.org/ labcert/TestApproval/index.htm
Assay DevelopmentIn-silico design- target gene, database search, multiplexing assessment
Primer and Probe optimization
Mastermix and MgCl+ optimization
Sensitivity (Determination of LOD with and without matrix)
Specificity
Inter/Intra assay reproducibility
Wadsworth Center Process for Molecular Assay Validation
Example
Mycobacterium tuberculosis complex-real-time PCR test
Experience with real-time PCRInstrumentationEase of use< 2 hoursPCR flow, closed systemInhibition test<$5.00 a test
Assay Development
Choose Target-IS6110Insertion element with a multi copy target (1 to 25 copies)Previously evaluated, Increased sensitivity, Sequence data
Evaluated 2 different primer/probe setsSavelkoul et al. *Desjardin et al. (primers were modified from publication)
Constructed inhibition controlTOPO cloned segment of fruit fly DNA containing primer binding sites specific to MTB assayDetected by additional probe while using same primers designed for IS6110 target
Optimize assayMastermix, MgCl2, probe, and primer titrations
*Savelkoul et al., J of Microb Methods 66 (2006) 177-180
Assay Validation
SensitivityAnalytical - M. tuberculosis (1 copy of IS6110) in bufferMatrix- M. tuberculosis (1 copy of IS6110) in sputum
Specificity37 members of MTB complex 24 M. tuberculosis strains (IS6110 copies from partial to 21)
49 NTM and other respiratory pathogens
Reproducibility
Sensitivity Results-analytical
Sensitivity determined to be 0.05 colony forming unit (cfu) per reaction
Sensitivity Results-sputum
Sensitivity determined to be 0.5 colony forming unit (cfu) per reaction in sputum specimens
Specimen Preparation Evaluation
Heat kill straight with no other treatmentEpicentre Masterpure DNA extraction KitEasyMag extractionProcess using IDI (Infectio Diagnostics, Inc., Quebec, Canada) lysis extraction
Currently: BD GeneOhm Lysis Kit Simple protocol: Vortex 5 minutes in lysis tube containing glass beads, heat @ 95 °C for 2 minutes
Assessment of best approach to achieve high sensitivity, no PCR inhibitors, ease of use, time
Validation of Home Brew Assays
BLINDED Study
Compare results to gold standard or FDA approved assayCompare results to results from another CLEP approved assaySpike clinical samples and compare to expected results
30 positives samples-10 must be close or no more than 10x LODMust be performed in matrix (blood, sputum). If no clinical samples available, seeded specimens can be utilized
Assay Validation
Side by side testing with GEN-PROBE® AMPLIFIED™ Mycobacterium Tuberculosis Direct (MTD) test (FDA approved)
Tested 291 samples for validation
87 0
9 190
3� 2�
Real-time PCR
MTD test NEG
NEG
POS
POS
INCONCLUSIVE
tDetermined to be culture positivelDetermined to be culture negative
*1 specimen PCR inhibited
Use of Appropriate Controls
Extraction controls- Lysis/ExtractionBacteria or virus preferred, if unavailable can use DNASeeded at a low level
Amplification controls (positive, NTC)
Inhibition testing controlControl that many labs do not test for or test for improperlyIdeally used as internal control in every sampleFor well established method can submit data from 100 samples per specimen type at a low level
CLEP approval of Broad-range Sequence based assays
New guidelines recently established
Detailed SOPM (controls, Taq, acceptable minimum sequence length, base calling)
Reporting algorithm (100%, <95%)
Databases utilized (public, private)
Blinded validation -30 samples (different species)
In silico proficiency test- 10 DNA sequences
Target specific guidelines in progress
CLEP Approval- Sequence-based Methods
Wadsworth Center has CLEP approved rpoB assay to determine mutations associated with rifampin resistance in MTB from culture
Development and validation of pyrosequencing assay for rapid sequence analysis of rpoB
Validation ongoing- all MTB complex PCR positive-specimensComparison to CLEP approved assay and gold standardPotential to have PCR and rpoB sequence results on day of specimen receipt<$1.00, 4 hours to resultAll specimens remain tested by cultureand traditional susceptibility panels
PPiATP Time
Light
Acknowledgements
Tanya Halse, Liz Nazarian, Danielle Wroblewski
Keith Derbyshire, Vincent Escuyer, Phyllis Cunningham, Jeff Driscoll
Christina Egan, Ron Limberger
Kirsten St. George, Amy Dean, Monica Parker, Jan Keithly, Vishnu Chaturvedi, Daryl Lamson
Mike Ryan, Vicky Derbyshire
Dick Jenny, Mike Neal- CLEP
DesignDesign
F1
TCTTC
Seq1
Rev
Mutations located in the 81 bp ofM. tuberculosis rpoB associatedwith rifampin resistance
Seq2
40%17%
3%1%
6%6%
GluGAA
3%
16% 7%
Mutations at WC 10/05 thru 12/07(n=70)
1%
1%
74%